VIDEO: Talquetamab shows promise in relapsed or refractory multiple myeloma
Click Here to Manage Email Alerts
In the 24 patients with relapsed or refractory multiple myeloma who received the phase 2 recommended dose of talquetamab, the overall response rate was 70%, according to phase 1 data presented at the virtual ASCO Annual Meeting.
This “very high response rate” was durable and seemed to deepen over time, suggesting talquetamab was a “very active agent,” Amrita Y. Krishnan, MD, FACP, director of Judy and Bernard Briskin Multiple Myeloma Center and professor of hematology/hematopoietic cell transplantation at City of Hope Cancer Center, told Healio in a video interview.
Talquetamab is a bispecific IgG4 antibody that binds to the novel target GPRC5D and CD3.
“We’re quite lucky now, it seems we have several bispecifics. Different targets all suggesting high efficacy, good safety and tolerability and some signals ... suggesting durability in these responses,” Krishnan said.
Collapse
Berdeja JG, et al. Abstract 8008. Presented at: ASCO Annual Meeting (virtual); June 4-8, 2021.
Read more about
Click Here to Manage Email Alerts